EZH2 is highly expressed in MYCN-amplified neuroblastoma, maintaining the tumor cells in an undifferentiated state, and EZH2 inhibition reduces neuroblastoma growth in vitro and in vivo [40]. Here, MYCN is linked to neoplasm.